Pharmaceuticals News and Research

RSS

Malvern Instruments to showcase new analytical tools at The Bioprocessing Summit in Boston

Malvern Panalytical is showcasing new analytical tools for biopharmaceutical applications on its exhibition booth at The Bioprocessing Summit in Boston from 19-23 August 2013.

From Malvern Panalytical 9 Aug 2013

Viewpoints: Fears of health law's adverse selection; GOP's 'fundamental miscalculation;' special deal for Congress keeps dissent low

Yet despite the care the administration took in establishing incentives and safeguards, even some of Obamacare's most committed backers are wondering whether the experiment will work as advertised - or, like Harvard's P.P.O., go off the rails along the way. Adverse selection is perhaps the direst threat. ... Healthier Americans will probably flock to cheaper bronze plans. And insurers will vie to enroll the healthy. In some states, big insurers have chosen not to participate in exchanges to avoid their strictures. On the outside, they could still sell cheap plans to skim off the healthy and avoid a rule that insurers on the exchanges must also offer more generous silver and gold plans (Eduardo Porter, 8/7).

9 Aug 2013

Drug-related emergency department visits increase among younger adults

A new report by the Substance Abuse and Mental Health Services Administration shows that some drug-related emergency department visits increased by 300 percent -- from 5,605 visits in 2005 to 22,949 visits in 2011. These visits, made by adults aged 18 to 34, were related to the nonmedical use of central nervous system stimulants. On average, about 30 percent of these visits also involved alcohol.

9 Aug 2013

TUM scientists decode typical protein profile of tumor cells

In what is the biggest study of its kind to date, researchers from Technische Universit-t M-nchen have identified over 10,000 different proteins in cancer cells. "Nearly all anti-tumor drugs are targeted against cellular proteins," says Prof. Bernhard K-ster, Head of the TUM Chair of Proteomics and Bioanalytics. "Identifying the proteome the protein portfolio of tumor cells increases our chances of finding new targets for drugs."

9 Aug 2013

CfPIE announces two new training courses for life science professionals

The Center for Professional Innovation and Education has announced two new EU regulations training courses for life science professionals. The new courses – to be presented in early December at the Berlin Hilton in Berlin, Germany, expands upon the thirty other CfPIE courses presented in Europe each year.

9 Aug 2013

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.

8 Aug 2013

UAH invents smart pill bottle that notifies you to take your medications

Patented at The University of Alabama in Huntsville, (UAH), a smart pill bottle that notifies you to take your medications or reminds you if you missed a dose could be en route to medicine cabinets as soon as 2015.

8 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Researchers develop nanoprobe technique to help treat fatal diseases more effectively

Researchers at the University of Southampton, in collaboration with colleagues at the University of Cambridge, have developed a technique to help treat fatal diseases more effectively.

8 Aug 2013

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

Johns Hopkins University receives $5.8M grant to research on causes of frailty in older adults

The federal government has awarded investigators at The Johns Hopkins University's schools of medicine and public health a multimillion-dollar, five-year grant to continue research designed to identify the causes of frailty in older adults, and speed the development of interventions to slow or stop it.

7 Aug 2013

Targacept reports net loss of $12.4 million for Q2 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the second quarter and six months ended June 30, 2013.

6 Aug 2013

TTY BIOPHARM receives Outstanding Company of the Year award

TTY BIOPHARM was awarded "Outstanding Company of the Year", the highest award given at the Bio Taiwan 2013 Exhibition. At the opening ceremony on July 18, Rong-Jing Lin, Chairman and General Manager of TTY BIOPHARM, received the prize from Ma Ying-jeou, President of Taiwan.

6 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67 percent in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA).

6 Aug 2013

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

...

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

Viewpoints: Shutting down the government over health law is 'nutty' idea; GOP's Obamacare playbook for summer recess

Led by Sens. Mike Lee and Ted Cruz, the GOP insurgents are threatening to shut down the government on Oct. 1 if the stopgap funding bill contains money for Obamacare. This is nuts. The president will never sign a bill defunding the singular achievement of his presidency. Especially when he has control of the Senate. Especially when, though a narrow 51 percent majority of Americans disapproves of Obamacare, only 36 percent favors repeal. President Obama so knows he'll win any shutdown showdown that he's practically goading the Republicans into trying. ... Every fiscal showdown has redounded against the Republicans (Charles Krauthammer, 8/1).

3 Aug 2013

Pharmaceuticals News and Research

Malvern Instruments to showcase new analytical tools at The Bioprocessing Summit in Boston

Viewpoints: Fears of health law's adverse selection; GOP's 'fundamental miscalculation;' special deal for Congress keeps dissent low

Drug-related emergency department visits increase among younger adults

TUM scientists decode typical protein profile of tumor cells

CfPIE announces two new training courses for life science professionals

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

UAH invents smart pill bottle that notifies you to take your medications

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Researchers develop nanoprobe technique to help treat fatal diseases more effectively

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Johns Hopkins University receives $5.8M grant to research on causes of frailty in older adults

Targacept reports net loss of $12.4 million for Q2 2013

TTY BIOPHARM receives Outstanding Company of the Year award

Ensemble Therapeutics initiates research and development collaboration with Novartis

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Viewpoints: Shutting down the government over health law is 'nutty' idea; GOP's Obamacare playbook for summer recess

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence